The BMY-28100 30-,ig-disk test was evaluated by using 615 clinical isolates. Regression analyses and error rates were determined, leading to the recommendation of 18-mm zone diameters (MIC correlate, .8.0 ,ug/ml) for susceptibility and c14-mm zone diameters (MIC correlate, .32 BMY-28100 is a recently studied, orally administered cephalosporin that has structural similarities with cefadroxil (position 7 p-hydroxy group) and cefixime (position 3 cispropenyl group) (2-5, 7, 12, 13). These modifications produce a spectrum of antimicrobial activity most similar to that of cefaclor, i.e. against Staphylococcus spp., beta-hemolytic streptococci, Streptococcus pneumoniae, beta-lactamaseproducing Haemophilus influenza, Neisseria gonorrhoeae, Escherichia coli, Klebsiella spp., Proteus mirabilis, and some strains of enteric pathogens, such as Salmonella spp. and Shigella spp. (3, 4, 7, (11) (12) (13) . In addition, measurable activity was observed against Enterococcus faecalis and cephalosporin-susceptible MIC breakpoint of s8.0 ,ug/ml (data on file; Bristol-Myers Co., Wallingford, Conn.). This contrasts with levels in serum observed with some new oral cephalosporins that may require susceptible breakpoints as low as sl.0 pg/ml (5, 6, 11) .
BMY-28100 is a recently studied, orally administered cephalosporin that has structural similarities with cefadroxil (position 7 p-hydroxy group) and cefixime (position 3 cispropenyl group) (2-5, 7, 12, 13) . These modifications produce a spectrum of antimicrobial activity most similar to that of cefaclor, i.e. against Staphylococcus spp., beta-hemolytic streptococci, Streptococcus pneumoniae, beta-lactamaseproducing Haemophilus influenza, Neisseria gonorrhoeae, Escherichia coli, Klebsiella spp., Proteus mirabilis, and some strains of enteric pathogens, such as Salmonella spp. and Shigella spp. (3, 4, 7, (11) (12) (13) . In addition, measurable activity was observed against Enterococcus faecalis and cephalosporin-susceptible MIC breakpoint of s8.0 ,ug/ml (data on file; Bristol-Myers Co., Wallingford, Conn.). This contrasts with levels in serum observed with some new oral cephalosporins that may require susceptible breakpoints as low as sl.0 pg/ml (5, 6, 11) .
In this report we present the results of studies with 30-,ug BMY-28100 disks that correlate the observed zones of inhibition with MICs. An additional quality control (QC) multilaboratory investigation determined preliminary guidelines for BMY-28100 tested by the broth microdilution method.
BMY-28100 was provided by Bristol-Myers. Other diag- the best zone criterion correlating with a susceptible MIC of -8.0 ,ug/ml would be .18 mm. This zone was identical to those for many other cephalosporins (9, 11) . The intermediate range would be 15 to 17 mm, correlating with a BMY-28100 MIC of 16 ,ug/ml. A zone for resistant isolates would be <14 mm, or an MIC of .32 ,ug/ml. However, the false-susceptible rate was unacceptably high (2.8% very major errors), although the false-resistant (major errors) and minor interpretive error rates were acceptable (Table 1) . Two genera, Haemophilus and Providencia, contributed the vast majority of false-susceptible zone diameters. When Providencia rettgeri, Providencia stuartii, and H. influenza strains (71 organisms) were deleted from the analyses, the very major errors were reduced from 2.8 to only 0.7%. The very major interpretive error rates among these problem genera ranged from 10% for beta-lactamase-positive H. influenzae to 38% for the Providencia spp. Results with the control 30-,ig cefuroxime disk produced results comparable to those in previous reports (8) .
The broth microdilution QC study required from each of six laboratories 20 MICs derived from trays prepared in their own facility. In addition, each laboratory performed five MICs on a broth microdilution tray common to all investigators. Four routinely used QC organisms were tested, and the results are summarized in Table 2 . Modes were clearly established for all four organisms.
BMY-28100 is an oral cephem with a spectrum very comparable to those of many currently utilized cephalosporins (2-4, 7, 11-13 
